Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: REPL stock price vs CTXR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CTXR's multiple
Needs Revenue / share.
Implied fair value · at REPL's multiple
Needs REPL P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: REPL FY 2026 (ended Mar 31, 2026) · CTXR FY 2022 (ended Sep 30, 2022). Fiscal years are not aligned.
Trendline
Nine fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
REPL carries the larger enterprise value at $1.23B against -$31.69M.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
REPLIMUNE GROUP, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.50x
-0.06x
Net debt / EBITDA
Leverage against operating earnings
0.60x
1.45x
Cash and equivalents
Liquid reserves on the balance sheet
$268.89M
$41.71M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
REPL vs AMGN
INCYTE CORP
REPL vs INCY
Blueprint Medicines Corp
REPL vs BPMC
Adaptive Biotechnologies Corp
REPL vs ADPT
Zomedica Corp.
REPL vs ZOM
Aquestive Therapeutics, Inc.
REPL vs AQST
ACADIA PHARMACEUTICALS INC
REPL vs ACAD
GILEAD SCIENCES, INC.
REPL vs GILD
AbbVie Inc.
REPL vs ABBV
$83.31M
-$6.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
